SGMO

[saffeysite1]

Sangamo Biosciences, Inc. engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The company's gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company's technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture. It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy.

Keep on watch, broke out to new high, wait for pullback to get in.

[stocky]

Applaud for this pick.

[saffeysite1]

THanks stocky.  Love the strong "W" formation of the chart, which just broke the neckline.

[stockpicker]

this is an exciting company, great pick!

will be the next ALNY

[cumulina]

Not a word from our community on this one?

I don't know the company, and do not own the stock.

But I thought the chart was pretty amazing!

[REALDEALS21]

Nice chart here, this one could be a takeover target !!

[setravis]

Sangamo BioSciences (SGMO) & Sigma-Aldrich (SIAL) Announce Alliance
..."to Develop Zinc Finger-Based Laboratory Research Reagents --- Companies Combine Proprietary Technologies to Create High Value Research Products"... , Tuesday July 10, 4:00 pm ET
http://biz.yahoo.com/prnews/070710/aqtu068.html?.v=16
Article related quotes:
http://finance.yahoo.com/q/cq?s=SGMO,SIAL&d=v6

Monday July 9...During the quarter Genentech formed a collaboration with Sangamo BioSciences Inc. over technology that regulates how genes work within a cell....
http://biz.yahoo.com/ap/070709/earnings_preview_genentech.html?.v=1

Symmetrical Triangle (continuation) Pattern...BreakOut !
Recent CandleStick Analysis
Bullish
Jul-09-2007 Bullish Engulfing 

52wk Range: 4.45 - 11.40
Volume: 3,724,121
Avg Vol (3m): 452,392

Technicals
Record Volume
Record Price High
Gap Up
Percentage Gainer
MACD is Bullish

Last Price Quote is:
19.08%above 13-day MA
30.58%above 50-day MA
RS Rating: 4 

Fundamentals
Earnings Expected on Jul 24

Key Data:
Market Cap (M): $293.15 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 07/24/2007
Last Analyst Rating: Strong Buy

[setravis]

New Strong Buy Rating.......
Analyst announces strong buy rating, Oversold...A rally may be back on!



52wk Range: 5.82 - 19.82
Volume: 1,025,218
Avg Vol (3m): 580,537

Technicals
Percentage Gainer

Fundamentals
Key Data:
Market Cap (M): $514.21 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 02/07/2008
Last Analyst Rating: Buy

[setravis]

Back above the 50-day...
Target $5-13, stop $3.95. Sangamo BioSciences. Back above the 50-day.

12-Jan-09 Co announces it has reached a major production capacity milestone as part of its agreement with Sigma-Aldrich Corporation (SIAL) to commercialize zinc finger nuclease reagents (ZFNs) for research applications. The milestone triggers a payment of $1.0 mln to Sangamo.


52wk Range: 1.82 - 14.53
Volume: 290,160
Avg Vol (3m): 389,241

Technicals
Close Above the 50-day MA

Last Price Quote is:
9.29%above 13-day MA
4.15%above 50-day MA
RS Rating: 23 

Fundamentals
Earnings Expected on Feb 4

Key Data:
Market Cap (M): $170.06 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 02/04/2009
Last Analyst Rating: Sell

[setravis]

Sangamo BioSciences Announces Fourth Quarter and Year-End 2008...

RICHMOND, Calif., Jan 28, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. (SGMO, Trade) today announced that the company will release its fourth quarter and year-end 2008 financial results on Wednesday, February 4, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-681-3378 for domestic callers and 719-325-4765 for international callers. The passcode for the call is 6408611. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 4, 2009 to midnight ET on February 11, 2009. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 6408611.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of the technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE Sangamo BioSciences, Inc.



http://www.sangamo.com 

Copyright (C) 2009 PR Newswire. All rights reserved

[Protocol Guy]

new research note from ZACKS Small cap research: